The independent medical news service

The high side-effect burden of metastatic breast cancer treatments warrants the development of innovative dosing strategies to maintain quality of life, suggest the results of an advocate-led survey of patients.

Adding the PD-L1 inhibitor durvalumab to neoadjuvant chemotherapy may improve survival outcomes in people with triple-negative breast cancer, show GeparNUEVO data presented at the 2021 ASCO Annual Meeting.

A de-escalated neoadjuvant regimen of pertuzumab and trastuzumab plus paclitaxel leads to “excellent” pathologic complete response rates and survival in people with hormone receptor-negative, HER2-positive early breast cancer, phase 2 study findings indicate.

Concurrent use of the ACE inhibitor lisinopril could help reduce the risk for left ventricular ejection fraction decline in women receiving trastuzumab and anthracyclines for HER2-positive early breast cancer, suggests US research.

Adding the BCL2 inhibitor venetoclax to fulvestrant does not improve outcomes for women with estrogen receptor-positive, HER2-negative locally advanced breast cancer resistant to endocrine and CDK4/6 inhibitor treatment, say the VERONICA investigators.

The novel CDK4/6 inhibitor dalpiciclib plus fulvestrant could be “a new treatment option” for patients who have received prior endocrine therapy for hormone receptor-positive advanced breast cancer, say the DAWNA-1 investigators.

The OlympiA study has demonstrated a significant reduction in the risk for recurrence and disease progression with adjuvant olaparib versus placebo in patients with HER2-negative, early-stage breast cancer and germline BRCA mutations.

An ¹⁸F-fluorodeoxyglucose positron emission tomography response-adapted treatment strategy could lead to improved quality of life for some patients with HER2-positive, early-stage breast cancer, study findings indicate.

The declines in breast cancer screening during the COVID-19 pandemic are more marked among women from minority communities and those living in rural areas, report US researchers.

The quality of life of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer remains largely unchanged by the addition of palbociclib to first-line fulvestrant, suggest data from the FLIPPER trial.

The BERENICE investigators report a low incidence of cardiac events with the use of pertuzumab–trastuzumab-based neoadjuvant and adjuvant regimens in patients with HER2-positive, early breast cancer after 5 years of follow-up.

Paired analysis of primary and relapsed breast cancer specimens shows that many HER2-negative patients switch between HER2-low and HER2-0 expression during disease progression.

Breast, prostate, and colorectal cancer screening rates declined sharply during the initial months of the COVID-19 pandemic in the USA, and while they subsequently recovered, a large deficit remains, study findings indicate.

Long-term results from the ShortHER trial of adjuvant trastuzumab de-escalation provide reassurance for patients with HER2-positive, early breast cancer who may need to discontinue treatment before completing the standard 1-year course.

TROPION-PanTumor01 trial findings suggest that the TROP2-directed antibody–drug conjugate datopotamab deruxtecan might offer a novel treatment option for patients with advanced triple-negative breast cancer.

The long-term benefit of endocrine therapy in premenopausal women with breast cancer may be influenced by molecular risk, suggest Swedish findings.

Early results from the GELATO trial point to the potential of atezolizumab plus carboplatin for the treatment of metastatic invasive lobular breast cancer.

Heavily pretreated patients with metastatic breast cancer characterized by a high tumor mutational burden are likely to derive “meaningful clinical benefit” from pembrolizumab monotherapy, say the TAPUR researchers.

Individuals with breast cancer and a BRCA1/2 variant experience comparable survival rates whether they are treated with breast-conserving therapy or mastectomy with or without radiotherapy, Chinese researchers suggest.

The American Heart Association has released a consensus statement on the management of cardiovascular disease in patients receiving hormonal therapies for breast or prostate cancer.